Imlunestrant

Imlunestrant
Clinical data
Other names	LY3484356
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (5R)-5-[4-[2-[3-(Fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol;
CAS Number	2408840-26-4;
PubChem CID	146603228;
ChemSpider	115010421;
UNII	9CXQ3PF69U;
KEGG	D12216;
ChEMBL	ChEMBL5095183;
Chemical and physical data
Formula	C29H24F4N2O3
Molar mass	524.516 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(CN1CCOC2=CC=C(C=C2)[C@@H]3C4=C5C=CC(=CC5=NC=C4C6=C(O3)C=C(C=C6)C(F)(F)F)O)CF;
	InChI InChI=1S/C29H24F4N2O3/c30-13-17-15-35(16-17)9-10-37-21-5-1-18(2-6-21)28-27-23-8-4-20(36)12-25(23)34-14-24(27)22-7-3-19(29(31,32)33)11-26(22)38-28/h1-8,11-12,14,17,28,36H,9-10,13,15-16H2/t28-/m1/s1; Key:UVBQMXOKKDCBJN-MUUNZHRXSA-N;

Imlunestrant is an experimental selective estrogen receptor degrader developed by Eli Lilly and Company for the treatment of some types of breast cancer.^[1]^[2]^[3]

Quick Facts Clinical data, Other names ...

References